AK119 + AK112 + pemetrexed + carboplatin

This is a four-drug combination comprising **AK119**, **AK112**, **pemetrexed**, and **carboplatin**. AK119 is a novel humanized IgG4 monoclonal antibody targeting CD73 (ecto-5'-nucleotidase), designed to inhibit immune suppression in the tumor microenvironment. AK112 is a first-in-class humanized IgG1 bispecific antibody targeting both PD-1 (programmed death-1) and VEGF (vascular endothelial growth factor), enhancing both immune checkpoint inhibition and anti-angiogenic effects[1][4][7]. Pemetrexed is a multi-targeted anti-folate chemotherapeutic (mostly known as Alimta), and carboplatin is a platinum-based chemotherapeutic. The combination is under investigation primarily for **advanced solid tumors, including non-small cell lung cancer and colorectal cancer**, leveraging synergistic immune modulation and cytotoxic effects[1][4][7].